Barry Quart Biography and Net Worth

Director of Kiniksa Pharmaceuticals International

Dr. Quart is the Chief Executive Officer and a director on the board of Connect Biopharma. Prior to joining Connect Biopharma, he served as the Chief Executive Officer of Heron Therapeutics, Inc. from May 2013 to April 2023, and served as a director of Heron from June 2012 to April 2023. Dr. Quart has over 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products.

In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through May 2013 and as a director through its acquisition by AstraZeneca PLC in June 2012. Previously, he was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from June 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in June 2015. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.

What is Barry D. Quart's net worth?: The estimated net worth of Barry D. Quart is at least $514.26 thousand as of June 9th, 2025. Dr. Quart owns 12,546 shares of Kiniksa Pharmaceuticals International stock worth more than $514,261 as of December 4th. This net worth evaluation does not reflect any other investments that Dr. Quart may own. Learn More about Barry D. Quart's net worth.
How do I contact Barry D. Quart?: The corporate mailing address for Dr. Quart and other Kiniksa Pharmaceuticals International executives is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. Kiniksa Pharmaceuticals International can also be reached via phone at (781) 431-9100 and via email at [email protected]. Learn More on Barry D. Quart's contact information.
Has Barry D. Quart been buying or selling shares of Kiniksa Pharmaceuticals International?: Barry D. Quart has not been actively trading shares of Kiniksa Pharmaceuticals International during the past quarter. Most recently, Barry D. Quart sold 12,336 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $30.39, for a transaction totalling $374,891.04. Following the completion of the sale, the director now directly owns 12,546 shares of the company's stock, valued at $381,272.94. Learn More on Barry D. Quart's trading history.
Who are Kiniksa Pharmaceuticals International's active insiders?: Kiniksa Pharmaceuticals International's insider roster includes Thomas Malley (Director), Michael Megna (Group Vice President of Finance and Chief Accounting Officer), Ross Moat (Executive Vice President, Chief Commercial Officer), John Paolini (Executive Vice President, Chief Medical Officer), Sanj Patel (CEO and Chairman of the Board), Barry Quart (Director), Mark Ragosa (CFO), and Eben Tessari (https://monarchcasino.com/corporategovernance_boardofdirectors.asp). Learn More on Kiniksa Pharmaceuticals International's active insiders.
Are insiders buying or selling shares of Kiniksa Pharmaceuticals International?: In the last year, insiders at the sold shares 57 times. They sold a total of 1,575,162 shares worth more than $51,430,265.98. The most recent insider tranaction occured on November, 26th when COO Eben Tessari sold 200 shares worth more than $8,578.00. Insiders at Kiniksa Pharmaceuticals International own 53.5% of the company. Learn More about insider trades at Kiniksa Pharmaceuticals International.
Information on this page was last updated on 11/26/2025.

Barry D. Quart Insider Trading History at Kiniksa Pharmaceuticals International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/11/2025	Sell	12,336	$30.39	$374,891.04	12,546
6/10/2025	Sell	8,212	$30.36	$249,316.32	12,546
6/9/2025	Sell	6,900	$30.26	$208,794.00	12,546
11/29/2022	Sell	21,959	$16.15	$354,637.85

Barry D. Quart Buying and Selling Activity at Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International Company Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Today's Range

Now: $40.99

$39.79

$41.48

50 Day Range

MA: $39.46

$36.49

$42.71

2 Week Range

Now: $40.99

$17.82

$42.98

Volume

331,068 shs

Average Volume

299,683 shs

Market Capitalization

$3.11 billion

P/E Ratio

91.09

Dividend Yield

N/A

Beta

0.02